Saturday, February 6, 2016

FDA approves four-in-one HIV pill

The FDA on Monday approved a once-a-day AIDS medicine that combines four drugs in one pill and is produced by Gilead Sciences, Inc.

FDA approves four-in-one HIV pill


The U.S. Food and Drug Administration on Monday approved a once-a-day AIDS medicine that combines four drugs in one pill and is produced by Gilead Sciences, Inc.

The drug is designed to treat HIV-1 infection in adults who have never been treated for HIV infection, according to the FDA.

Brand-named Stribild, the pill contains two previously approved HIV drugs plus two new drugs.

“Through continued research and drug development, treatment for those infected with HIV has evolved from multi-pill regimens to single-pill regimens,” Dr. Edward Cox, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research said in a statement. “New combination HIV drugs like Stribild help simplify treatment regimens.” A link to the FDA statement is here.

The Centers for Disease Control and Prevention said in its most recent yearly report on HIV/AIDS that New Jersey and Pennsylvania were among the top 10 states in the number of new cases being diagnosed. A link to the CDC report is here.

Earlier this year, the FDA approved the first over-the-counter, at-home test for HIV, which is made by Orasure of Bethlehem, Pa. A link to the Inquirer story on that approval is here.

The Kaiser Family Foundation HIV/AIDS Fact Sheet from July of 2012 is here.


Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter